SEC Tracker
Get the app

Zenas BioPharma ZBIO

Zenas BioPharma announces new obexelimab data.

Form
8-K
Filed
Importance
Routine
  1. Phase 3 INDIGO open-label extension showed 93% flare-free rate at 12 months.
  2. Obexelimab reduced glucocorticoid toxicity by 11.4 points vs. placebo at week 52.
  3. Vaccinations during treatment-free window led to 86% seroimmunity for influenza.
  4. Median glucocorticoid doses were 0 mg in the extension trial.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Zenas BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.